Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
8
Bullish
2
Bearish
16
Neutral
8
Bullish
22
Bearish
12
Neutral
0
Bullish
20
Bearish
4
Neutral
8
Bullish
2
Bearish
4
Neutral
8
Bullish
2
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Veerhealth Care Ltd. is an Indian GMP/ISO contract manufacturer and marketer of ayurvedic OTC drugs, oral care, cosmetics and personal care formulations, operating a large manufacturing complex in Vapi and selling under its Ayuveer brand while offering private‑label and contract manufacturing services domestically and internationally.
Veerhealth Care Ltd. secured USFDA clearance for its Drug (OTC) plant and a U.S. labeler code, enabling direct exports to the USA; this rare small‑cap regulatory approval materially supports higher‑volume export orders and validates the company’s ‘Local to Global’ strategic ambition to expand international revenue.
The company has backward‑integrated packaging via Veer Plast, installed brush tufting and trimming lines, and enlarged plant footprint to 60,000 sq. ft.; combined filling and packaging capacities (for example 0.75 million tubes/month) indicate operational readiness to scale production for large private‑label and export contracts.
Financially, FY26 reported net sales of Rs.32.48 crores with a Q4 spike to Rs.16.76 crores; management forecasts steep ramps to Rs.102.98 crores and Rs.152.47 crores in coming periods, implying execution risks but signaling management confidence that export and contract wins will convert to substantial revenue growth.
Veerhealth has strengthened customer relationships through onboarding of a leading FMCG group and a marketplace brand, while Ayuveer is expanding on e‑commerce platforms such as Myntra, Amazon, Nykaa and Flipkart, combining B2B contract revenue potential with direct‑to‑consumer distribution channels.
Pharmaceuticals & Biotechnology
Pharmaceuticals
99 Cr
Low Risk
75.8
34.8
0.5
4.3
52.00
16.70
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY25
Investor Presentation
Q4 FY24
Veerhealth Care Ltd (NIYATILEAS) is currently trading at 49.27 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Veerhealth Care Ltd. is an Indian GMP/ISO contract manufacturer and marketer of ayurvedic OTC drugs, oral care, cosmetics and personal care formulations, operating a large manufacturing complex in Vapi and selling under its Ayuveer brand while offering private‑label and contract manufacturing services domestically and internationally. Veerhealth Care Ltd. secured USFDA clearance for its Drug (OTC) plant and a U.S. labeler code, enabling direct exports to the USA; this rare small‑cap regulatory approval materially supports higher‑volume export orders and validates the company’s ‘Local to Global’ strategic ambition to expand international revenue. The company has backward‑integrated packaging via Veer Plast, installed brush tufting and trimming lines, and enlarged plant footprint to 60,000 sq. ft.; combined filling and packaging capacities (for example 0.75 million tubes/month) indicate operational readiness to scale production for large private‑label and export contracts. Financially, FY26 reported net sales of Rs.32.48 crores with a Q4 spike to Rs.16.76 crores; management forecasts steep ramps to Rs.102.98 crores and Rs.152.47 crores in coming periods, implying execution risks but signaling management confidence that export and contract wins will convert to substantial revenue growth. Veerhealth has strengthened customer relationships through onboarding of a leading FMCG group and a marketplace brand, while Ayuveer is expanding on e‑commerce platforms such as Myntra, Amazon, Nykaa and Flipkart, combining B2B contract revenue potential with direct‑to‑consumer distribution channels.
Over the past 52 weeks, Veerhealth Care Ltd has traded between a low of ₹16.70 and a high of ₹52.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Veerhealth Care Ltd has a market capitalization of approximately 98.53. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Veerhealth Care Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 75.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 98.53 Cr, Veerhealth Care Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Veerhealth Care Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Veerhealth Care Ltd is 75.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
104.20 | 107 Cr | 23.95 | 0.76 | 3.36 | 4.94 | 6.74 | 3.01 | ||
49.47 | 104 Cr | 25.63 | 0.56 | 0.00 | 8.06 | 8.98 | 1.68 | ||
28.92 | 102 Cr | — | 2.14 | 0.00 | -29.76 | -20.97 | -5.07 | ||
92.00 | 102 Cr | 17.97 | 1.73 | 0.22 | 9.79 | 13.29 | 4.71 | ||
49.27 | 99 Cr | 75.80 | 4.30 | 0.00 | 2.96 | 6.55 | 3.46 | ||
136.40 | 94 Cr | — | 20.42 | 0.00 | 67.65 | -85.76 | -4.24 | ||
6.87 | 93 Cr | 20.82 | 1.19 | 0.00 | 6.03 | 8.35 | 3.45 | ||
| Median: 7 Co. | — | 49.47 | 102 Cr | 23.95 | 1.73 | 0.00 | 6.03 | 6.74 | 3.01 |
